Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study-Reference-Cited by-同舟云学术

Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study

Published:2014-08-13 Issue:2 Volume:50 Page:238-248
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Hayashi Norio,Mobashery Niloufar,Izumi Namiki

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-014-0979-2.pdf

Reference14 articles.

1. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53(1):39–43.

2. Guidelines for the management of hepatitis. C virus infection: first edition, May 2012, the Japan Society of Hepatology. Hepatol Res. 2013;43(1):1–34.

3. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49(1):138–47.

4. McCauley JA, McIntyre CJ, Rudd MT, et al. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J Med Chem. 2010;53(6):2443–63.

5. Olsen DB, Davies ME, Handt L, et al. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother. 2011;55(2):937–9.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C virus (HCV) : Development of anti-HCV agents and anti-HCV therapy;Okayama Igakkai Zasshi (Journal of Okayama Medical Association);2020-12-01

2. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials;Journal of Clinical and Experimental Hepatology;2019-07

3. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world;The Korean Journal of Internal Medicine;2019-07-01

4. Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men;Clinical and Translational Science;2017-08-10

5. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings;Liver International;2017-03-17